Articles from Chai Discovery

Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence.

Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration agreement with argenx, a leading immunology innovation company.

Chai Discovery, the company engineering AI models to discover new molecules, today announced a $400M Series C fundraise to further accelerate progress.

Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Novartis to advance the discovery of therapeutic antibodies using artificial intelligence.

Chai Discovery, the AI company engineering models to discover new molecules, today announced that certain Chai Discovery frontier AI model capabilities will be made available to companies participating in the Lilly TuneLab platform.

Chai Discovery, the company engineering AI models to discover new molecules, today announced a license agreement with leading biopharmaceutical company Pfizer.

Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Eli Lilly and Company (Lilly) to accelerate biologics discovery using artificial intelligence.

Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules, today announced its $130 million Series B financing round co-led by Oak HC/FT and General Catalyst. This round of financing values the company at $1.3 billion.

Chai Discovery, the AI company that predicts and reprograms the interactions between biochemical molecules to accelerate life-changing therapeutics, today announced its $70 million Series A financing round.

Chai Discovery, which builds frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules, today announced a breakthrough in the de novo design of antibodies. The company’s latest model, Chai-2, demonstrates a remarkable antibody design hit rate close to 20%. Prompted with just the target and epitope, Chai-2 successfully designs all complementarity-determining regions (CDRs) entirely from scratch—a breakthrough in a field where traditional techniques, including those based on AI, consistently show hit rates below 0.1%.